Insmed Plunges 17% — When the “Perfect Game” Ends
Insmed's stock fell 17% following the failure of its drug Brinsupri in a Phase 2 study, which undermined its potential for treating inflammation. An acquisition news did not offset the negative impact of the drug trial results.